Ultragenyx

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, focused on developing innovative treatments for rare and ultra-rare genetic diseases. Founded in 2010 by Emil D. Kakkis, M.D., Ph.D., the company is publicly traded on NASDAQ under the ticker symbol RARE. Ultragenyx is dedicated to addressing unmet medical needs in the rare disease community through meaningful engagement with patients and their caregivers. The company develops therapies primarily for metabolic diseases, neurological disorders, and other rare genetic conditions. Notable products include Crysvita for X-linked hypophosphatemia, Dojolvi for long-chain fatty acid oxidation disorders, and Mepsevii for mucopolysaccharidosis VII. Ultragenyx has a robust pipeline with multiple programs in various stages of development, reflecting its commitment to advancing treatments through research and development. With a total of 652 employees as of December 2023, Ultragenyx operates commercially in the United States and collaborates globally on research initiatives. The company also emphasizes corporate sustainability and aims to positively impact patients while considering broader societal and environmental responsibilities.